Limits...
Protection of trigonelline on experimental diabetic peripheral neuropathy.

Zhou JY, Zhou SW - Evid Based Complement Alternat Med (2012)

Bottom Line: The mechanisms leading to diabetic peripheral neuropathy are complex and there is no effective drug to treat it.As an active component of several traditional Chinese medicines, trigonelline has beneficial effects on diabetes with hyperlipidemia.These findings suggest that trigonelline has beneficial effects for diabetic peripheral neuropathy through glucagon-like peptide-1 receptor/p38 mitogen-activated protein kinases signaling pathway, nerve conduction velocity, antioxidant enzyme activity, improving micropathological changes of sciatic nerve and decreasing lipid peroxidation.

View Article: PubMed Central - PubMed

Affiliation: Base for Drug Clinical Trial, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.

ABSTRACT
The mechanisms leading to diabetic peripheral neuropathy are complex and there is no effective drug to treat it. As an active component of several traditional Chinese medicines, trigonelline has beneficial effects on diabetes with hyperlipidemia. The protective effects and the mechanism of trigonelline on diabetic peripheral neuropathy were evaluated in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Rats were divided into four groups at the end of week 2: control, diabetes, diabetes + trigonelline (40 mg/kg), and diabetes + sitagliptin (4 mg/kg). After 48-week treatment, technologies of nerve conduction, cold and hot immersion test, transmission electron microscopy, real-time PCR, and Western blotting were applied. Serum glucose, serum insulin, insulin sensitivity index, lipid parameters, body weight, sciatic nerve conduction velocity, nociception, glucagon-like peptide-1 receptor mRNA and protein, total and phosphorylated p38 mitogen-activated protein kinases protein expression, malonaldehyde content, and superoxide dismutase activity were altered in diabetic rats, and were near control levels treated with trigonelline. Slight micropathological changes existed in sciatic nerve of trigonelline-treated diabetic rats. These findings suggest that trigonelline has beneficial effects for diabetic peripheral neuropathy through glucagon-like peptide-1 receptor/p38 mitogen-activated protein kinases signaling pathway, nerve conduction velocity, antioxidant enzyme activity, improving micropathological changes of sciatic nerve and decreasing lipid peroxidation.

No MeSH data available.


Related in: MedlinePlus

Effect of trigonelline on glucose of diabetic rats. Data are given as mean ± SD (n = 10). *P < 0.01 versus control rats; #P < 0.01 versus diabetes rats.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3526196&req=5

fig1: Effect of trigonelline on glucose of diabetic rats. Data are given as mean ± SD (n = 10). *P < 0.01 versus control rats; #P < 0.01 versus diabetes rats.

Mentions: Before drug administration (week 0), diabetic rats had high baseline fasting blood glucose levels. Blood glucose level of diabetic rats increased significantly comparing to that of the control ones. During drug treatment, trigonelline gradually decreased fasting blood glucose to normal level (Figure 1). HbA1c level of diabetic rats was significantly higher than that of the control ones. Treatment with trigonelline and sitagliptin for 48 weeks reverted the increased diabetic HbA1c level to near the control ones. Diabetic rats had significant increased-serum insulin concentration and decreased-insulin sensitivity index when compared with control ones. Trigonelline treatment reversed serum insulin level and insulin sensitivity index, but did not for sitagliptin. The TC and TG levels of diabetic rats were significantly higher than those of the control ones. Treatment with trigonelline for 48 weeks significantly decreased TC and TG levels, but sitagliptin did not affect these lipid metabolic parameters. Control rats grew faster than the other group ones and body weight of diabetic rats continued to increase (data not shown). The weight gain between initial (week 0) and final (week 48) body weight of control rats were remarkably higher than that of the other group ones. At weeks 48, trigonelline, but not sitagliptin, treatment obviously reduced diabetic weight gain (Table 1).


Protection of trigonelline on experimental diabetic peripheral neuropathy.

Zhou JY, Zhou SW - Evid Based Complement Alternat Med (2012)

Effect of trigonelline on glucose of diabetic rats. Data are given as mean ± SD (n = 10). *P < 0.01 versus control rats; #P < 0.01 versus diabetes rats.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3526196&req=5

fig1: Effect of trigonelline on glucose of diabetic rats. Data are given as mean ± SD (n = 10). *P < 0.01 versus control rats; #P < 0.01 versus diabetes rats.
Mentions: Before drug administration (week 0), diabetic rats had high baseline fasting blood glucose levels. Blood glucose level of diabetic rats increased significantly comparing to that of the control ones. During drug treatment, trigonelline gradually decreased fasting blood glucose to normal level (Figure 1). HbA1c level of diabetic rats was significantly higher than that of the control ones. Treatment with trigonelline and sitagliptin for 48 weeks reverted the increased diabetic HbA1c level to near the control ones. Diabetic rats had significant increased-serum insulin concentration and decreased-insulin sensitivity index when compared with control ones. Trigonelline treatment reversed serum insulin level and insulin sensitivity index, but did not for sitagliptin. The TC and TG levels of diabetic rats were significantly higher than those of the control ones. Treatment with trigonelline for 48 weeks significantly decreased TC and TG levels, but sitagliptin did not affect these lipid metabolic parameters. Control rats grew faster than the other group ones and body weight of diabetic rats continued to increase (data not shown). The weight gain between initial (week 0) and final (week 48) body weight of control rats were remarkably higher than that of the other group ones. At weeks 48, trigonelline, but not sitagliptin, treatment obviously reduced diabetic weight gain (Table 1).

Bottom Line: The mechanisms leading to diabetic peripheral neuropathy are complex and there is no effective drug to treat it.As an active component of several traditional Chinese medicines, trigonelline has beneficial effects on diabetes with hyperlipidemia.These findings suggest that trigonelline has beneficial effects for diabetic peripheral neuropathy through glucagon-like peptide-1 receptor/p38 mitogen-activated protein kinases signaling pathway, nerve conduction velocity, antioxidant enzyme activity, improving micropathological changes of sciatic nerve and decreasing lipid peroxidation.

View Article: PubMed Central - PubMed

Affiliation: Base for Drug Clinical Trial, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China.

ABSTRACT
The mechanisms leading to diabetic peripheral neuropathy are complex and there is no effective drug to treat it. As an active component of several traditional Chinese medicines, trigonelline has beneficial effects on diabetes with hyperlipidemia. The protective effects and the mechanism of trigonelline on diabetic peripheral neuropathy were evaluated in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Rats were divided into four groups at the end of week 2: control, diabetes, diabetes + trigonelline (40 mg/kg), and diabetes + sitagliptin (4 mg/kg). After 48-week treatment, technologies of nerve conduction, cold and hot immersion test, transmission electron microscopy, real-time PCR, and Western blotting were applied. Serum glucose, serum insulin, insulin sensitivity index, lipid parameters, body weight, sciatic nerve conduction velocity, nociception, glucagon-like peptide-1 receptor mRNA and protein, total and phosphorylated p38 mitogen-activated protein kinases protein expression, malonaldehyde content, and superoxide dismutase activity were altered in diabetic rats, and were near control levels treated with trigonelline. Slight micropathological changes existed in sciatic nerve of trigonelline-treated diabetic rats. These findings suggest that trigonelline has beneficial effects for diabetic peripheral neuropathy through glucagon-like peptide-1 receptor/p38 mitogen-activated protein kinases signaling pathway, nerve conduction velocity, antioxidant enzyme activity, improving micropathological changes of sciatic nerve and decreasing lipid peroxidation.

No MeSH data available.


Related in: MedlinePlus